The impact of water vapor thermal therapy of the prostate (rezūm) on sexual functions: a narrative review

Atif A. Katib¹, Khaled El Esaily²

Abstract

Background: Senile prostate enlargement is an age-related condition. Many sexually active patients fear formal prostate surgeries owing to their negative impact on sexual performance. Minimally invasive procedures, including prostate water vapor thermal therapy (Rezūm®), were devised to make ends meet. This study aims to present a comprehensive narrative synthesis about the impact of prostate water vapor therapy on sexual functions.

Methods: A narrative literature review was performed in May 2023, using MEDLINE, Cochrane Library, Ovid-Embase, Scopus, Science Direct, and Google Scholar; for the MeSH term “rezum AND sexual functions”. Selected reports were published articles from 2018 to date (the last 5 years). Only open-access journals in English were analyzed. Efforts were made to focus on the 2 main domains of sexual functions; erection and ejaculation.

Results: As per the concise MeSH term “rezum AND sexual functions”, a score of 207 hits appeared on the initial search. After eliminating duplicate and irrelevant papers, only 7 articles fulfilled the inclusion criteria and were subjected to analysis. The analyzed articles were critically appraised to point out the studies’ strengths and limitations. The gathered data were found to be consistent with one another as no outliers were detected.

Conclusion: Water vapor thermal therapy of the prostate showed satisfying preservation of erectile function with minimal ejaculatory dysfunction.

Keywords: Rezum, Water Vapor Therapy, Steam Prostate, Sexual Functions, Benign Prostatic Hyperplasia

Background

The prostatic gland plays a pivotal role in men's urinary, sexual, and fertility functions. Benign prostatic hyperplasia (BPH) is a common urologic condition affecting aging men and responsible for lower urinary tract symptoms (LUTS) in nearly 80% of men aged 50 or over [1]. Along with LUTS, worsening of sexual function is a common occurrence in men with BPH [2,3,4].
Health and Care Excellence (NICE) of the UK in 2018. Shortly after, the procedure spread out across the globe [16].

Evidence Acquisition
A comprehensive bibliographic search on the MEDLINE, Cochrane Library, Ovid-Embase, Scopus, Science Direct, and Google Scholar databases was conducted in May 2023. The MeSH term “rezum AND sexual functions” was used. Only open-access journals in English were tracked for information relevant to WVTT and its probable sexual consequences. Selected reports were published articles from 2018 up to date. Letters to the editor, editorial comments, and case reports were excluded. The two major domains of sexual dysfunctions, namely, erectile and ejaculatory were focused on. Relevant contents were critically appraised to point out the studies’ strengths and limitations.

Evidence Synthesis
This narrative review provides an overview of the current literature revolving around WVTT and its probable sexual drawbacks. Furthermore, the included studies were subjected to critical appraisal. Precise keywords of “rezum and sexual functions”, were used to ensure a deep search with no confounders. A score of 207 hits appeared on the initial search. After eliminating duplicate and irrelevant papers, only 7 full-text articles fulfilled the inclusion criteria and were subjected to analysis (Figure 1). Owing to the nature of the erection and ejaculation functions; coupled with the research instrument being a questionnaire; the study outcomes were utterly subjective. Most of the evaluation questionnaires are self-administered. Misunderstanding is likely as participants could find it hard to differentiate retrograde ejaculation (RE) from anejaculation. These two terms are often pooled in the literature, especially when the evaluation method is not detailed [14,17,18]. However, the pooled data in this research were found to be consistent with one another as no eccentric outcomes were detected (Table 1). In 2018, Kevin and associates targeted the Medical Therapy of Prostatic Symptoms (MTOPS) trial’s participants. They used sexual function data from sexually active cohorts in the MTOPS study; where 1,209 were randomized to doxazosin, finasteride, combination drugs, and placebo, and 86 sexually active men who received thermal therapy [23]. MTOPS study participants completed the Brief Male Sexual Function Inventory (BMSFI), whereas men in the WVTT arm completed the International Index of Erectile Function (IIEF) and the Male Sexual Health Questionnaire (MSHQ) [19]. Researchers found that the drug cohort suffered from worsening sexual desire, erection, and ejaculation functions. On the other hand, the WVTT cohort had no significant impact on sexual functions throughout the 3 years after the procedure. This article has the advantage of including high-quality data from 2 large randomized controlled trials (RCTs) in subjects with similar baseline inclusion criteria for LUTS severity and prostate size. In fact, it is the first longitudinal assessment of sexual function domains restricted to sexually active men treated with drugs or a single minimally invasive surgical treatment. A pivotal limitation of the study is that it is funded by the same body that introduced the Rezum system.

In 2019, Leong and associates reviewed the literature for articles about sexual functions after various BPH procedures. They reported that current surgical therapies available for the treatment of BPH are associated with a substantial risk of both ejaculatory and erectile functions. However, many of the novel minimally invasive treatment alternatives such as the UroLift®, Rezum®, and Aquablation®, have demonstrated the ability to preserve postoperative sexual function to a better degree. In addition, they reported these procedures having comparable safety, durability, and efficacy to current gold standard therapies [20]. In 2021, Kevin and associates published a multicenter RCT where 15 centers randomized 197 participants to WVTT (treatment arm) and sham procedure (control arm); and followed them for 5 years. The prostate size included was 30–80 cc. Participants were allowed to cross over if they qualified after 3 months of the study outset. Erectile and ejaculatory functions were quantitatively assessed at baseline and yearly thereafter. Results of the per-protocol analysis were reported previously. The current post-hoc analysis was performed on all treated subjects who were sexually active at baseline with no other surgical or medical management for BPH during the 5-year study period. One hundred thirty-six participants ended up in the treatment group while 61 remained in the control. At the end of the study participants completed the IIEF-EF and the MSHQ ejaculatory dysfunction (EjD) forms. A post-hoc analysis was performed. Subjects with normal sexual functions at baseline had little change in functions over 5 years. Subjects with baseline medical history of ED and EjD showed a slight decline over time that was not clinically significant [21]. The results of this work are limited by the post-hoc nature of the analysis and attrition over the 5-year follow-up; yet provide long-term evidence of durable outcomes after treatment with WVTT without impact on sexual function scores. Notably, the results represent a wide range of prostate volumes that could influence sexual outcomes. Moreover, observing 53 controls crossing over, optionally, to receive WVTT treatment while none reported crossing the other way around goes in favor of the treatment arm. The ethical controversies surrounding sham procedures cannot be deflected. In 2021, a narrative review was conducted by Couteau and associates for publications between 1990-2020 about the impact of medical and surgical treatments of the enlarged prostate on ejaculatory functions. They compared various BPH drug classes and surgical procedures as to what could be sex friendly. Out of the 65 articles in the final analysis, they reported that minimally invasive procedures including WVTT were devised to preserve antegrade ejaculation with promising short-term outcomes. They accomplish the mission by preserving 7.5 mm of tissue lateral, and 10 mm proximal to the verumontanum. In this work, the large number of articles included in the final analysis could be a point of strength. Moreover, the anatomical detail of tissue preservation surrounding the verumontanum is unique to this paper [22]. In 2021, Shing and associates reviewed various minimally invasive treatments for BPH focusing on their impact on erection and ejaculation. They included systematic reviews & meta-analysis articles published on the PubMed platform up to Jul. 2020. Researchers stated that while there was no reported incidence of de novo ED; 2.9% of patients reported reduced ejaculatory volume which subsequently decreased to 1.5% at 3 months while
the initial 4.0% risk of immediate postoperative anejaculation disappeared 3 months later [23]. In 2022, Manfredi and associates conducted a systematic review & meta-analysis to discuss the effect of different BPH procedures on erection and ejaculation functions. A total of 151 studies investigating 20,531 patients were included. Forty-eight RCTs evaluating 5,045 individuals were eligible for the meta-analysis. The pooled analysis showed no statistically significant changes in ejaculation functions and the IIEF-5 score compared with the baseline for the TURP procedure. Researchers concluded that erectile function appears to be unaffected by most surgical procedures for BPH. RE is a very common adverse event of BPH surgery, although emerging minimally invasive surgical procedures could be associated with a lower risk [26]. The large number of articles reviewed is a major strength of this study. On the other hand, a substantial number of articles (67, 44.4%) used non-validated tools to evaluate erectile and ejaculatory functions. In 2023, Cindolo and associates published a large multicenter cohort study. For 5 years, they followed all patients with symptomatic BPH who underwent WVTT at 8 institutions and analyzed the urinary and sexual outcomes. A total of 426 patients were eligible for the study; 232 in Group A, and 194 in Group B. Patients in Group B had a higher American Society of Anesthesiologists (ASA) score, prostate volume, and postvoid residues. On using the IPSS and the IIEF, researchers found no differences in urinary and sexual outcomes [27]. In addition to the intriguing large number of participants involved, the study revealed information relevant to patients with different risk factors. Noteworthy, the prime objective of the study was to compare the sexual and urinary outcomes of WVTT patients meeting the inclusion criteria of the RCT with unselected patients.

Conclusion
Water vapor thermal therapy of the prostate showed satisfying preservation of erectile function with a low risk of ejaculatory dysfunction.

Table 1: Synopsis of the narrative review

<table>
<thead>
<tr>
<th>Study</th>
<th>Year of publication</th>
<th>The conclusion verbatim</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>McVary et al. [23]</td>
<td>2018</td>
<td>WVTT has no significant impact on sexual functions</td>
<td>(S) data analyzed from 2 large RCTs&lt;br&gt;(L) the use of 2 different sexual function inventories&lt;br&gt;(L) the study is industry-sponsored</td>
</tr>
<tr>
<td>Leong et al. [20]</td>
<td>2019</td>
<td>WVTT preserves sexual functions</td>
<td>---</td>
</tr>
<tr>
<td>McVary et al. [19]</td>
<td>2021</td>
<td>WVTT causes sexual functions to decline over time, yet not statistically significant</td>
<td>(S) large multicenter RCT&lt;br&gt;(S) optional cross-over&lt;br&gt;(L) the nature of the post hoc analysis</td>
</tr>
<tr>
<td>Couteau et al. [22]</td>
<td>2021</td>
<td>WVTT preserves antegrade ejaculation with promising short-term outcomes</td>
<td>(S) large No. of articles reviewed&lt;br&gt;(S) the anatomical detail of tissues maintaining antegrade ejaculation</td>
</tr>
<tr>
<td>Shin Ng and, Chung [24]</td>
<td>2021</td>
<td>WVTT has no reported incidence of ED; while a few patients reported reduced ejaculatory volume</td>
<td>(S) systematic reviews &amp; meta-analysis study&lt;br&gt;(L) only articles on PubMed studied</td>
</tr>
<tr>
<td>Manfredi et al. [26]</td>
<td>2022</td>
<td>WVTT doesn`t affect erection but could have a low risk of RE</td>
<td>(S) large RCT&lt;br&gt;(L) considerable No. of articles used non-validated tools</td>
</tr>
<tr>
<td>Cindolo et al. [27]</td>
<td>2023</td>
<td>researchers found no differences between the 2 cohorts in urinary and sexual outcomes</td>
<td>(S) large multicenter cohort study&lt;br&gt;(L) has additional unrelated study objective</td>
</tr>
</tbody>
</table>

N.B. (WVTT) water vapor thermal therapy, (S) strength of the study, (L) limitation of the study, (RE) retrograde ejaculation
Abbreviation
BPH: Benign Prostatic Hyperplasia; LUTS: Lower Urinary Tract Symptoms; ED: Erectile Dysfunction; RE: Retrograde Ejaculation; TUPR: Transurethral Resection of The Prostate; WVTT: Water Vapor Thermal Therapy; FDA: Food and Drug Administration; NICE: National Institute for Health and Care Excellence; MTOPS: Medical Therapy of Prostatic Symptoms; BMSFI: Brief Male Sexual Function Inventory; IIEF: International Index of Erectile Function; MSHQ: Male Sexual Health Questionnaire; RCTs: Randomized Controlled Trials; IPSS: International Prostate Symptom Score; ASA: American Society of Anesthesiologists

Declaration
Acknowledgment
None

Funding
The authors received no financial support for their research, authorship, and/or publication of this article.

Availability of data and materials
Data will be available by emailing atifikatib@gmail.com

Authors’ contributions
Atif Katib (AK) is the lead author who wrote the first draft, drew the chart, designed the table, and the research idea is his. Khalid Al-Easly (KA-E) did data mining and shared his patient's data and his own experience. All authors read and approved the final manuscript.

Ethics approval and consent to participate
We conducted the research following the declaration of Helsinki; however, the review articles need no ethical approval.

Consent for publication
Not applicable

Competing interest
The authors declare that they have no competing interests.

Author Details
1Urology consultant at King Abdulaziz Hospital, Makkah, Saudi Arabia.
2Urology consultant at Urology Department, Theodor Bilharz Research Institute TBRI, Cairo, Egypt.

References